DRKS00025314已完成不适用
A prospective, non-interventional, multicenter observational study on quality of life, documentation of key allergic symptoms/medication and application patterns of SLIT LAIS® cat in patients with cat allergy. - ProCAT
ofarma Deutschland GmbH0 个研究点目标入组 111 人开始时间: 2021年5月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 111
研究概览
简要总结
The studied population exhibited improvements in quality of life and complaint profiles using RQLQ(S)-12-SA, RC-CSMS, visual scales, AA-CSMS, and asthma control assessment based on GINA criteria. There were 7 adverse drug reactions in total, with most patients having recovered during the study. There were no serious adverse drug reactions. The study was limited by its observational and exploratory design, smaller patient population than planned, and early termination.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 5 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Patients can be included if they meet the following criteria:
- •Diagnosis of IgE-mediated allergic diseases of the immediate type, such as allergic rhinitis, allergic conjunctivitis (conjunctivitis) and allergic bronchial asthma, due to sensitization to cat epithelia is given, proven by standardized routine tests such as skin prick test, specific IgE or provocation:
- •The decision to initiate immunotherapy against cat allergy was made independently of and before inclusion in this NIS; Patients who have already started LAIS® cats treatment can be recruited, provided that all necessary baseline data can be taken from the medical record. (Due to the prospective design, the start of SIT with LAIS® cats should not be older than November 2020 for a study to be considered.)
- •Signed written informed consent. Parents (guardians) and the patient's consent are required for patients under 18 years of age.
- •The minimum age the doctor decides to put a patient on therapy is = 5 years.
排除标准
- •Contraindications according to the current SmPC, including:
- •Malignant neoplastic diseases with current disease value.
- •Serious autoimmune diseases, immunodeficiency, immunodeficiency, immunosuppression.
- •Chronic inflammatory diseases.
- •Acute inflammation of the oral cavity with severe symptoms.
- •Moderate or severe uncontrolled bronchial asthma.
- •Illnesses in which the use of adrenaline is contraindicated (please note special warnings in the product information)
- •pregnancy.
- •Hypersensitivity to one of the other ingredients in the (see section 6.1 SmPC).
研究者
相似试验
已完成
不适用
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)Multiple Sclerosis, Relapsing-RemittingNCT01110993Merck KGaA, Darmstadt, Germany65
已完成
不适用
A Multicenter Prospective Study of Quality of Life in Adult ScoliosisScoliosisNCT00854828Washington University School of Medicine286
尚未招募
不适用
Quality of Life in Patients Treated With Leadless PacemakersLeadless Micra Transcatheter PacemakerQuality of LifeNCT05958836Shanghai Zhongshan Hospital246
尚未招募
不适用
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical PracticePolycythemia VeraNCT05566535Multinational Center for Quality of Life Research, Russia32
已完成
不适用
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) IndicationVenous ThrombosisNCT01805544Bayer113